Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OKUR by emailGet an email when OKUR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OKUR, unsubscribe in one click. Privacy
📣 What OKUR Says Is Next
first half of 2027 · “OnKure plans to submit an IND application to the FDA for OKI - 345 in the first half of 2027.”
Company press release, Aug 4, 2026 · SEC filing
first half of 2027 · “OnKure plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OKI - 355 in the first half of 2027.”
Company press release, Aug 4, 2026 · SEC filing
first half of 2027 · ““Both OKI-355 and OKI-345 continue to advance through IND-enabling activities and remain on track for planned IND submissions in the first half of 2027.”
Company press release, Aug 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OKUR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OKUR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.